Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Capecitabine Market by Indication (Colorectal Cancer, Breast Cancer, Others) , by Drug Type (Branded, Generic) by End User (Hospitals, Homecare, Specialty Clinics, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033

A03017

Pages: 280

Charts: 59

Tables: 136

Capecitabine Market Research, 2033

The global capecitabine market size was valued at $0.4 billion in 2023, and is projected to reach $0.7 billion by 2033, growing at a CAGR of 5% from 2024 to 2033. The major factors driving the growth of the capecitabine market are surge in prevalence of cancer, improved healthcare access, rise in research and development to enhancing the efficacy and safety profiles of capecitabine.

Market Introduction and Definition

Capecitabine is an oral chemotherapy medication used in the treatment of various cancers, including breast, colon, and rectal cancers. It belongs to a class of drugs known as antimetabolites, which work by interfering with the growth and spread of cancer cells. Capecitabine is a prodrug, meaning it is converted into its active form, 5-fluorouracil (5-FU) , in the body. Once converted, 5-FU inhibits the synthesis of DNA and RNA in cancer cells, ultimately leading to their death. Unlike traditional chemotherapy drugs administered intravenously, capecitabine is taken orally, usually in the form of tablets. This offers convenience to patients and allows for outpatient treatment in many cases. Furthermore, capecitabine has shown promise in combination therapies, enhancing its effectiveness in targeting cancer cells while minimizing adverse effects. Its versatility in combination with other drugs or therapies allows for tailored treatment approaches based on individual patient needs and cancer characteristics. For instance, oxaliplatin and capecitabine is a chemotherapy combination known as Xelox, which is used for the treatment of bowel cancer (colorectal cancer) , cancer of the food pipe (oesophagus) , and stomach cancer. 

Key Takeaways 

  • The capecitabine market study covers 20 countries. The research includes a segment analysis of each country in terms of value ($million) for the projected period 2023-2032.

  • More than 1, 500 product literatures, industry releases, annual reports, and other such documents of major energy storage system industry participants along with authentic industry journals, trade associations' releases, and government websites have been reviewed for generating high-value industry insights.

  • The study integrates high-quality data, professional opinions and analysis, and critical independent perspectives. The research approach is intended to provide a balanced view of global markets and to assist stakeholders in making educated decisions to achieve their most ambitious growth objectives.

 Key Market Segments

  • By Indication
    • Colorectal Cancer
    • Breast Cancer
    • Others
  • By Drug Type
    • Branded
    • Generic
  • By End User
    • Hospitals
    • Homecare
    • Specialty Clinics
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • Australia
      • India
      • South Korea
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • Saudi Arabia
      • South Africa
      • Rest of LAMEA

 
Key Market Players

  • Pfizer Inc.
  • Eli Lilly and Company.
  • Sanofi
  • Novartis AG
  • Dr. Reddy’s Laboratories Ltd.
  • Mylan N.V.
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: CAPECITABINE MARKET, BY INDICATION

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Indication

    • 4.2. Colorectal Cancer

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Breast Cancer

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Others

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: CAPECITABINE MARKET, BY DRUG TYPE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Drug Type

    • 5.2. Branded

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Generic

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: CAPECITABINE MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Hospitals

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Homecare

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Specialty Clinics

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Others

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: CAPECITABINE MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Indication

      • 7.2.3. Market Size and Forecast, By Drug Type

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Capecitabine Market

        • 7.2.6.1. Market Size and Forecast, By Indication
        • 7.2.6.2. Market Size and Forecast, By Drug Type
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada Capecitabine Market

        • 7.2.7.1. Market Size and Forecast, By Indication
        • 7.2.7.2. Market Size and Forecast, By Drug Type
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico Capecitabine Market

        • 7.2.8.1. Market Size and Forecast, By Indication
        • 7.2.8.2. Market Size and Forecast, By Drug Type
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Indication

      • 7.3.3. Market Size and Forecast, By Drug Type

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Capecitabine Market

        • 7.3.6.1. Market Size and Forecast, By Indication
        • 7.3.6.2. Market Size and Forecast, By Drug Type
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany Capecitabine Market

        • 7.3.7.1. Market Size and Forecast, By Indication
        • 7.3.7.2. Market Size and Forecast, By Drug Type
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy Capecitabine Market

        • 7.3.8.1. Market Size and Forecast, By Indication
        • 7.3.8.2. Market Size and Forecast, By Drug Type
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain Capecitabine Market

        • 7.3.9.1. Market Size and Forecast, By Indication
        • 7.3.9.2. Market Size and Forecast, By Drug Type
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK Capecitabine Market

        • 7.3.10.1. Market Size and Forecast, By Indication
        • 7.3.10.2. Market Size and Forecast, By Drug Type
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia Capecitabine Market

        • 7.3.11.1. Market Size and Forecast, By Indication
        • 7.3.11.2. Market Size and Forecast, By Drug Type
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe Capecitabine Market

        • 7.3.12.1. Market Size and Forecast, By Indication
        • 7.3.12.2. Market Size and Forecast, By Drug Type
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Indication

      • 7.4.3. Market Size and Forecast, By Drug Type

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Capecitabine Market

        • 7.4.6.1. Market Size and Forecast, By Indication
        • 7.4.6.2. Market Size and Forecast, By Drug Type
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan Capecitabine Market

        • 7.4.7.1. Market Size and Forecast, By Indication
        • 7.4.7.2. Market Size and Forecast, By Drug Type
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India Capecitabine Market

        • 7.4.8.1. Market Size and Forecast, By Indication
        • 7.4.8.2. Market Size and Forecast, By Drug Type
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea Capecitabine Market

        • 7.4.9.1. Market Size and Forecast, By Indication
        • 7.4.9.2. Market Size and Forecast, By Drug Type
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia Capecitabine Market

        • 7.4.10.1. Market Size and Forecast, By Indication
        • 7.4.10.2. Market Size and Forecast, By Drug Type
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand Capecitabine Market

        • 7.4.11.1. Market Size and Forecast, By Indication
        • 7.4.11.2. Market Size and Forecast, By Drug Type
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia Capecitabine Market

        • 7.4.12.1. Market Size and Forecast, By Indication
        • 7.4.12.2. Market Size and Forecast, By Drug Type
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia Capecitabine Market

        • 7.4.13.1. Market Size and Forecast, By Indication
        • 7.4.13.2. Market Size and Forecast, By Drug Type
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific Capecitabine Market

        • 7.4.14.1. Market Size and Forecast, By Indication
        • 7.4.14.2. Market Size and Forecast, By Drug Type
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Indication

      • 7.5.3. Market Size and Forecast, By Drug Type

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Capecitabine Market

        • 7.5.6.1. Market Size and Forecast, By Indication
        • 7.5.6.2. Market Size and Forecast, By Drug Type
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa Capecitabine Market

        • 7.5.7.1. Market Size and Forecast, By Indication
        • 7.5.7.2. Market Size and Forecast, By Drug Type
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia Capecitabine Market

        • 7.5.8.1. Market Size and Forecast, By Indication
        • 7.5.8.2. Market Size and Forecast, By Drug Type
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE Capecitabine Market

        • 7.5.9.1. Market Size and Forecast, By Indication
        • 7.5.9.2. Market Size and Forecast, By Drug Type
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina Capecitabine Market

        • 7.5.10.1. Market Size and Forecast, By Indication
        • 7.5.10.2. Market Size and Forecast, By Drug Type
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA Capecitabine Market

        • 7.5.11.1. Market Size and Forecast, By Indication
        • 7.5.11.2. Market Size and Forecast, By Drug Type
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. F. Hoffmann-La Roche Ltd.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Mylan N.V.

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Teva Pharmaceutical Industries Ltd.

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Sanofi

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Pfizer Inc.

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Dr. Reddy’s Laboratories Ltd.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Novartis AG

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Bayer AG

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Eli Lilly And Company.

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Merck And Co., Inc.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL CAPECITABINE MARKET, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL CAPECITABINE MARKET FOR COLORECTAL CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL CAPECITABINE MARKET FOR BREAST CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL CAPECITABINE MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL CAPECITABINE MARKET, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL CAPECITABINE MARKET FOR BRANDED, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL CAPECITABINE MARKET FOR GENERIC, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL CAPECITABINE MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL CAPECITABINE MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL CAPECITABINE MARKET FOR HOMECARE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL CAPECITABINE MARKET FOR SPECIALTY CLINICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL CAPECITABINE MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL CAPECITABINE MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. NORTH AMERICA CAPECITABINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. NORTH AMERICA CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 16. NORTH AMERICA CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 18. U.S. CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 19. U.S. CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 20. U.S. CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 21. CANADA CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 22. CANADA CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 23. CANADA CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 24. MEXICO CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 25. MEXICO CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 26. MEXICO CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 27. EUROPE CAPECITABINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 28. EUROPE CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 29. EUROPE CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 31. FRANCE CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 32. FRANCE CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 33. FRANCE CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 34. GERMANY CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 35. GERMANY CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 36. GERMANY CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 37. ITALY CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 38. ITALY CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 39. ITALY CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 40. SPAIN CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 41. SPAIN CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 42. SPAIN CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 43. UK CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 44. UK CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 45. UK CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 46. RUSSIA CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 47. RUSSIA CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 48. RUSSIA CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 49. REST OF EUROPE CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 50. REST OF EUROPE CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 51. REST OF EUROPE CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 52. ASIA-PACIFIC CAPECITABINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 53. ASIA-PACIFIC CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 54. ASIA-PACIFIC CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 55. ASIA-PACIFIC CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 56. CHINA CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 57. CHINA CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 58. CHINA CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 59. JAPAN CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 60. JAPAN CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 61. JAPAN CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 62. INDIA CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 63. INDIA CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 64. INDIA CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 65. SOUTH KOREA CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 66. SOUTH KOREA CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 67. SOUTH KOREA CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 68. AUSTRALIA CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 69. AUSTRALIA CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 70. AUSTRALIA CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 71. THAILAND CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 72. THAILAND CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 73. THAILAND CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 74. MALAYSIA CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 75. MALAYSIA CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 76. MALAYSIA CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 77. INDONESIA CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 78. INDONESIA CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 79. INDONESIA CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 80. REST OF ASIA PACIFIC CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 81. REST OF ASIA PACIFIC CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 83. LAMEA CAPECITABINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 84. LAMEA CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 85. LAMEA CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 86. LAMEA CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 87. BRAZIL CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 88. BRAZIL CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 89. BRAZIL CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 90. SOUTH AFRICA CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 91. SOUTH AFRICA CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 92. SOUTH AFRICA CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 93. SAUDI ARABIA CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 94. SAUDI ARABIA CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 95. SAUDI ARABIA CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 96. UAE CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 97. UAE CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 98. UAE CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 99. ARGENTINA CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 100. ARGENTINA CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 101. ARGENTINA CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 102. REST OF LAMEA CAPECITABINE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 103. REST OF LAMEA CAPECITABINE, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 104. REST OF LAMEA CAPECITABINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 105. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 106. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 107. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
  • TABLE 108. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 109. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 110. MYLAN N.V.: KEY EXECUTIVES
  • TABLE 111. MYLAN N.V.: COMPANY SNAPSHOT
  • TABLE 112. MYLAN N.V.: OPERATING SEGMENTS
  • TABLE 113. MYLAN N.V.: PRODUCT PORTFOLIO
  • TABLE 114. MYLAN N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 116. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 117. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 118. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 119. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 120. SANOFI: KEY EXECUTIVES
  • TABLE 121. SANOFI: COMPANY SNAPSHOT
  • TABLE 122. SANOFI: OPERATING SEGMENTS
  • TABLE 123. SANOFI: PRODUCT PORTFOLIO
  • TABLE 124. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 125. PFIZER INC.: KEY EXECUTIVES
  • TABLE 126. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 127. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 128. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 129. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 130. DR. REDDY’S LABORATORIES LTD.: KEY EXECUTIVES
  • TABLE 131. DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 132. DR. REDDY’S LABORATORIES LTD.: OPERATING SEGMENTS
  • TABLE 133. DR. REDDY’S LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 134. DR. REDDY’S LABORATORIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 135. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 136. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 137. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 138. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 139. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 140. BAYER AG: KEY EXECUTIVES
  • TABLE 141. BAYER AG: COMPANY SNAPSHOT
  • TABLE 142. BAYER AG: OPERATING SEGMENTS
  • TABLE 143. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 144. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 145. ELI LILLY AND COMPANY.: KEY EXECUTIVES
  • TABLE 146. ELI LILLY AND COMPANY.: COMPANY SNAPSHOT
  • TABLE 147. ELI LILLY AND COMPANY.: OPERATING SEGMENTS
  • TABLE 148. ELI LILLY AND COMPANY.: PRODUCT PORTFOLIO
  • TABLE 149. ELI LILLY AND COMPANY.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 150. MERCK AND CO., INC.: KEY EXECUTIVES
  • TABLE 151. MERCK AND CO., INC.: COMPANY SNAPSHOT
  • TABLE 152. MERCK AND CO., INC.: OPERATING SEGMENTS
  • TABLE 153. MERCK AND CO., INC.: PRODUCT PORTFOLIO
  • TABLE 154. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL CAPECITABINE MARKET SEGMENTATION
  • FIGURE 2. GLOBAL CAPECITABINE MARKET
  • FIGURE 3. SEGMENTATION CAPECITABINE MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN CAPECITABINE MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCAPECITABINE MARKET
  • FIGURE 11. CAPECITABINE MARKET SEGMENTATION, BY BY INDICATION
  • FIGURE 12. CAPECITABINE MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. CAPECITABINE MARKET FOR BREAST CANCER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. CAPECITABINE MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. CAPECITABINE MARKET SEGMENTATION, BY BY DRUG TYPE
  • FIGURE 16. CAPECITABINE MARKET FOR BRANDED, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. CAPECITABINE MARKET FOR GENERIC, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. CAPECITABINE MARKET SEGMENTATION, BY BY END USER
  • FIGURE 19. CAPECITABINE MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. CAPECITABINE MARKET FOR HOMECARE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. CAPECITABINE MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. CAPECITABINE MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 24. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 25. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 26. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 27. COMPETITIVE DASHBOARD
  • FIGURE 28. COMPETITIVE HEATMAP: CAPECITABINE MARKET
  • FIGURE 29. TOP PLAYER POSITIONING, 2024
  • FIGURE 30. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 31. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 32. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 33. MYLAN N.V.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. MYLAN N.V.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. MYLAN N.V.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. SANOFI: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. SANOFI: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. SANOFI: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. PFIZER INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. PFIZER INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. DR. REDDY’S LABORATORIES LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. DR. REDDY’S LABORATORIES LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. DR. REDDY’S LABORATORIES LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. NOVARTIS AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. NOVARTIS AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. BAYER AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. BAYER AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. BAYER AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. ELI LILLY AND COMPANY.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. ELI LILLY AND COMPANY.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. ELI LILLY AND COMPANY.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 57. MERCK AND CO., INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 58. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 59. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Capecitabine Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved